Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer

• Awalpreet S. Chadha ,

  Contributed equally to this work with: Awalpreet S. Chadha, Heath D. Skinner

  Affiliation Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Heath D. Skinner ,

  Contributed equally to this work with: Awalpreet S. Chadha, Heath D. Skinner

  Affiliation Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Jillian R. Gunther,

  Affiliation Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Mark F. Munsell,

  Affiliation Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Prajnan Das,

  Affiliation Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Bruce D. Minsky,

  Affiliation Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Marc E. Delclos,

  Affiliation Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Deyali Chatterjee,

  Affiliation Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Huamin Wang,

  Affiliation Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Marilyn Clemons,

  Affiliation Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Geena George,

  Affiliation Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Pankaj K. Singh,

  Affiliation Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Matthew H. Katz,

  Affiliation Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Jason B. Fleming,

  Affiliation Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Milind M. Javle,

  Affiliation Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Robert A. Wolff,

  Affiliation Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Gauri R. Varadhachary,

  Affiliation Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Christopher H. Crane,

  Affiliation Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
•  [ ... ],
• Sunil Krishnan

  * E-mail: skrishnan@mdanderson.org

  Affiliation Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• [ view all ]
• [ view less ]